Biofrontera AG reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 28.79 million compared to EUR 30.35 million a year ago. Net income was EUR 38.32 million compared to net loss of EUR 13.02 million a year ago. Basic earnings per share from continuing operations was EUR 0.69 compared to basic loss per share from continuing operations of EUR 0.24 a year ago. Diluted earnings per share from continuing operations was EUR 0.68 compared to diluted loss per share from continuing operations of EUR 0.24 a year ago.